Xu et al. further highlighted another endogenous RIPK1 inhibitor, TAK1, involved in ALS.  Downregulation of TAK1 in TBK1 mutant mice exacerbates various hallmark features of ALS such as neuroinflammation and TDP-43 aggregation. Here, TARDBP is linked to amyotrophic lateral sclerosis.